These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 38668051)

  • 1. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.
    Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
    Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and classification of myelodysplastic syndromes.
    Hasserjian RP; Germing U; Malcovati L
    Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The International Consensus Classification of myelodysplastic syndromes and related entities.
    Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
    Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
    Lucero J; Al-Harbi S; Yee KWL
    Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Capodanno I; Neri A; Morabito F; Vigna E; Gentile M
    Eur J Haematol; 2024 Jun; 112(6):860-869. PubMed ID: 38294126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Zavras PD; Sinanidis I; Tsakiroglou P; Karantanos T
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
    Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
    Abdulbaki R; Pullarkat ST
    Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
    AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
    Maggioni G; Della Porta MG
    Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.
    Hochman MJ; DeZern AE
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):573-582. PubMed ID: 38594129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N; Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E; Weber UM; Gore S
    Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
    Venugopal S; Mascarenhas J; Steensma DP
    Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic abnormalities in myelodysplastic syndrome: an overview.
    Kawankar N; Vundinti BR
    Hematology; 2011 May; 16(3):131-8. PubMed ID: 21669051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
    Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.